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A Selective Approach to Bleeding Esophageal Varices! 
Glyn G, Jamieson, MD,* Irwin B. Faris, MD,* and John Ludbrook, MD* 
It is possible that the best results of treatment for bleeding 
esophageal varices will come when a selective approach is 
used. In patients bleeding acutely and in patients with poor 
liver function shunt operations should be avoided, and a 
direct attack on the varices with either sclerosant therapy. 
percutaneous obliteration, or staple gun gastro-esophageal 
transsection should be carried out. In patients who have 
stopped bleeding, or those in whom elective treatment is 
being undertaken, the best operation at present appears to 
be selective distal splenorenal shunt. 
History of the Portacaval Shunt 
In 1876 B.F Lautenbach first suggested joining the portal 
venous system to the systemic venous system for the treat-
ment of ascites. When an abstract of his report was pub-
lished in Russia, Nicolai Vladimirovich Eck used it to carry 
out such an anastomosis (1), the first report in the literature. 
Eck reported in the Military Medical Journal of Russia in 
1877 that he had joined the end of the portal vein to the 
vena cava in eight dogs: "the animal recovers after such an 
operation, its nutritional status improves gradually, and 
remains in perfect health thereafter." Considering that of 
the eight dogs he operated on, seven were dead within a 
week afterwards, it would seem that the surgical trait of 
forgetting one's bad results did not originate in this century! 
The other dog lived for two and a half months and then 
escaped to an unknown fate on the Russian steppes. Eck 
himself was called up into active military service and faded 
into obscurity. However, Hahn, working in Pavlov's labora-
tory, continued this study and found that ofthe dogs which 
survived, many died later of what was called "meat intox-
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ication" (since designated hepatic encephalopathy by 
Sheila Sherlock). 
In the human, the first shunt between the portal and 
systemic systems was performed by the French surgeon 
Vidal and reported in 1902. He noted that unless protein 
was excluded from his patient's diet, the patient became 
severely intoxicated (2). Although Vidal's patient lived for 
several years, the problem of "meat intoxication" as well 
as the high mortality rate of the operation prevented the 
portacaval shunt from gaining widespread acceptance in 
the armamentarium of the surgeon. It was not established 
as a routine operation until the pioneering efforts of Allen 
Oldfather Whipple and his team at Columbia University in 
New York in the early 1940s. 
Allen Whipple was encouraged to examine the possibility 
of portacaval shunting for several reasons. First, he was 
dissatisfied with the various devascularization operations 
used to control bleeding varices, as they had both a high 
mortality rate and a high rebleeding rate. Second, he was 
aware of the portacaval shunts that the unrelated George 
Whipple in Rochester New York had performed in dogs 
with relative impunity. The freedom from "meat intoxica-
t ion" in these dogs was due at least in part to the fact that 
they were fed on meat-free extract. Indeed, this extract was 
used in a research program which led to the discovery of 
the role of vitamin B12 in pernicious anemia and to a 
Nobel Prize for George Whipple (3). 
But with the work of Allen Whipple the modern era of 
shunting was born (4). It became obvious that the operation 
of joining the portal to the systemic circulation was ex-
tremely effective in attaining its primary aim, that is, to stop 
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bleeding from gastro-esophageal varices. As a result, en-
thusiasm for the portacaval shunt in portal hypertension 
grew until the operation was being used not only to treat 
patients who had bled from their varices (therapeutic 
shunts), but also to treat patients who had varices and had 
not bled from them (prophylactic shunts). Furthermore, the 
operation was even being performed on patients with and 
without varices who had ascites. In the early 1960s the use 
of portacaval shunting reached an uncrftical zenith, but 
ever since it has been on the decline. 
For one thing, improved medical management meant that 
the operation was rarely indicated for ascites except when 
a block in the hepatic venous circulation occurred, a very 
uncommon situation. Also, when thoughtful clinicians 
began to look more carefully at the natural history of portal 
hypertension, it became clear that some patients never 
bled from their varices and therefore could only lose by 
having a major operation (5). 
At this stage, several prospective, randomized trials were 
set up to study both prophylactic and therapeutic por-
tacaval shunts. With the former, when it was apparent that 
patients who were shunted tended to have a poorer chance 
of survival than those who were not shunted, the procedure 
was abandoned as a prophylactic therapy for bleeding (6). 
With the latter, although trials in the U.S. have shown a 
trend in favor of shunted patients, there was a 7% statistical 
probability that the result was due to chance (7). However, 
the method of dying certainly differed in the two groups of 
patients. In the shunted group, the patients died more often 
of "meat intoxication", i.e., hepatic failure, while in the 
unshunted group they died of hemorrhage from their 
varices. 
In an editorial in Gastroenterology in 1974, Harold Conn 
said that "we must learn either to select better who should 
be shunted or to shunt better those we select." (7). 
"Selecting Better" 
Hemodynamic studies 
Hemodynamic studies have been carried out to try to 
achieve better selection of patients for surgery. Child's 
clinical classification of patients into Class A, B, and C, 
based on their liver function, has been quite useful in 
predicting operative mortality (8). But it was hoped that 
more accurately identifying the level of the obstruction to 
portal flow and the degree and quality of portal flow might 
have proved a better way to predict the outcome of surgery. 
Hemodynamic studies have revealed that the flow of blood 
in the portal vein in portal hypertension may be hepatope-
tal, so that in spite of increased pressure, blood still flows 
toward the liver through the portal vein. There may be very 
little flow in either direction in the portal vein, sometimes 
blood flowing toward the liver and sometimes away; and 
there may be hepatofugal blood flow in which the portal 
vein acts as an outflow tract from the liver and in fact 
decompresses hepatic sinusoids (9). Patients with no sig-
nificant flow in either direction and no encephalopathy 
should do best with traditional end-to-side portacaval 
shunt. With this operation a shunt neither takes blood away 
from the liver nor stops blood flowing out from the liver. 
However, those patients with forward flow in the portal 
vein might be expected to develop hepatic encephalopathy 
since a vital source of blood supply to the liver has been 
removed. Lastly, those patients in whom the portal vein is 
acting as an outflow tract to the liver might be at risk of 
developing ascites after an end-to-side portacaval shunt, as 
the pressure in the liver would be increased when the 
outflow tract was interrupted. Unfortunately, the situation is 
probably more complex, as It has been shown that while 
there is some correlation of prognosis with hemodynamic 
staging, the correlation, in fact, is not as good as Child's 
classification, which has been used for over ten years. One 
of the difficulties has been to accurately determine pre-
operatively the amount and direction of portal flow in the 
portal vein. One group's conclusion about hemodynamic 
studies is that at present they are costly, time-consuming, 
and unrewarding (10). 
Poor risk groups 
Several groups of patients with bleeding esophageal varices 
have a high mortality rate after operation. First, there are 
the patients who are acutely bleeding at the time of por-
tacaval surgery. Operating in an emergency situation is 
always hazardous. Even when patients are carefully se-
lected, the operative mortality rate is in the 30% range; and 
ifone takes unselected patients, the mortality rate is much 
higher, usually in excess of 50% (11). For this reason, the 
mesocaval shunt operation was introduced and probably 
given its greatest boost by Theodore Drapanas. He reported 
on a group of poor risk patients who had an operative 
mortality of only 8% in 25 cases (12). But subsequent 
reports have not been so optimistic; a recent prospective 
study by Malt and his colleagues showed a 75% mortality 
rate for the mesocaval shunt used in the emergency situa-
tion (13). Several retrospective series have shown high 
mortality rates also. In other words, the figures look de-
pressingly like those for portacaval shunt. Indeed, there 
seems little reason, hemodynamically, why the figures 
should be different. At present, it would appear that shunt 
operations are contraindicated in acutely bleeding gastro-
esophageal varices. These patients should be treated by 
standard medical measures such as blood replacement, 
vasopressine infusions, either intravenously or intraar-
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terially, and a Sengstaken-Blakemore tube. If bleeding con-
tinues, in spite of these measures, then three choices are 
available. 
1. Sclerosant therapy 
The direct injection of sclerosant agents into bleeding 
varices has been used in Europe for many years but is only 
now beginning to gain greater acceptance elsewhere. In 
Belfast, Rodgers and his group reported in a retrospective 
study that they stopped bleeding in 93% of patients, al-
though there was an in-hospital mortality rate of 26% (14). 
Terblanche and his group in Cape Town recently published 
a prospective study that showed similar figures; they were 
able to stop bleeding in 92% of patients with a 25% 
mortality rate (15). While these mortality rates may still 
appear high, they must be compared with the mortality 
rates of shunt operations in unselected patients in similar 
circumstances. 
2. Percutaneous transhepatic obliteration of varices 
The placement of a catheter percutaneously through the 
liver into radicles of the portal vein is an attractive tech-
nique because it allows the radiologist to selectively oblit-
erate the veins wh ich are causing bleeding. Several 
substances have been used as obliterating material, among 
them, gelfoam and cyanoacrylate. Although initial enthusi-
asm for this technique has been tempered somewhat by the 
moderately high incidence of portal vein thrombosis fol-
lowing its use (16), nevertheless if sclerosant therapy fails or 
is not available it would seem a better alternative than a 
shunt operation in an acutely bleeding situation. 
3. Staple gun gastro-esophageal transsection 
This is but a variant of the older operation of esophageal 
transsection and/or under-running of varices. However, it 
is quicker than those operations and produces a better 
gastro-esophageal anastomosis. It can be accomplished 
with a reasonably low mortality, although it has not yet 
been properly assessed for acutely bleeding patients (17). If 
sclerosant therapy or percutaneous obliteration cannot be 
carried out, this operation may be the most conservative 
way to produce the desired result of stopping bleeding in 
the emergency situation. 
Besides acutely bleeding patients, two other categories of 
patients do badly with shunt surgery: patients with alco-
holic hepatitis and hyaline necrosis, and patients with 
Child's Class C liver function. If a patient falls into this latter 
group in spite of a nutritionally adequate diet and absti-
nence from alcohol, then again the operative mortality rate 
with shunt operations is prohibitively high (5). Since the life 
expectancy of such a patient is short, the same procedures 
as for emergency bleeding should be considered, that is. 
sclerosant therapy, percutaneous transhepatic obliteration 
of varices, or staple gun gastro-esophageal transsection. 
The same can be said for patients with acute alcoholic 
hepatitis with hyaline necrosis, who also have a high 
mortality rate with shunt operations (18). 
Avoiding shunt surgery altogether 
Although direct operations on esophageal varices had been 
used for many years, it was because of his dissatisfaction 
with this approach that Allen Whipple inftially performed 
portacaval shunts. Nevertheless, some groups have contin-
ued to use these operations and have recently reported 
good results with them. Thus, Sugiura reported that in the 
elective use of a thoraco-abdominal esophago-gastric de-
vascularization, esophageal transsection, splenectomy and 
selective vagotomy, and pyloroplasty, there was only a 
2.6% mortality rate in 224 patients. In 52 patients who 
were bleeding acutely he reported an 11.5% mortality rate. 
Furthermore, the rebleeding rate was only 7% in his series 
(19). Yamamoto has carried out a similar operation from an 
abdominal approach. He performed an esophago-gastrec-
tomy, splenectomy and trunkal vagotomy and pyloroplasty 
electively in 64 patients with a mortality rate of 11% and a 
rebleeding rate of only 14% (20). While these figures are 
very impressive, the figures from the Chapel Hill group are 
not. They carried out a similar procedure on 60 patients, 
but reported a 35% operative mortality rate and a 50% 
rebleeding rate (21). The cause ofthe cirrhosis and patient 
selection methods may well explain some ofthe difference 
in these figures, but, nevertheless, the discrepancy is very 
large. 
"Shunting Better" 
At present, two operations are the main contenders for 
better shunts. Most people agree that if significant blood 
flows up the portal vein toward the liver, then that blood 
supply should not be removed. The first of the new opera-
tions attempts to keep blood flowing to the liver by ar-
terializing the portal vein stump, while the second leaves 
intact the superior mesenteric vein flow to the portal vein. 
Arterialization of the portal vein 
Maillard has reported a standard portacaval shunt followed 
by an anastomosis of the splenic artery to the portal vein 
stump (22). Adamsons has also used this technique and 
recently reported on lower flow arterialization using micro-
vascular techniques to anastomose the right gastro-epiploic 
artery to the portal vein stump (23). However, neither of 
these techniques has yet found widespread acceptance. 
The operation which has slowly gained acceptance is the 
selective distal splenorenal shunt. 
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Selective distal splenorenal shunt (Warren shunt) 
In 1967 Warren, Zeppa, and Fomon (24) first described this 
operation in which the splenic vein is dissected from the 
bed of the pancreas, divided near its central end, turned 
down, and anastomosed end-to-side to the left renal vein. 
The left gastric (coronary) vein, the right gastro-epiploic 
vein, and any other venous connections between the portal 
system and the stomach are then divided so that the 
superior mesenteric vein flow to the liver remains intact. 
This operation has met with growing acceptance, as both 
retrospective and prospective studies have shown that the 
incidence of hepatic encephalopathy is indeed lower fol-
lowing the procedure when compared with other por-
tasystemic shunts. The rebleeding rate also remains 
acceptably low (25,26). 
We have used this operation in a small groupof 18 patients 
with three postoperative deaths: a Child's Class B patient 
who developed infected ascites and died of overwhelming 
sepsis; a Child's Class B patient who died of massive 
bleeding from varices on the 12th postoperative day in 
spite of a widely patent shunt revealed at autopsy; and a 
Child's Class C patient who developed progressive liver 
failure and died on the 27th postoperative day. Of the 15 
remaining patients, one developed an early shunt throm-
bosis and had a mesocaval shunt constructed, while an-
other died two years after the operation of liver failure due 
to continuing alcoholism. Thirteen patients are alive after 
12-48 months, follow-up. They have had no recurrent 
hemorrhage, and one patient has had overt portal systemic 
encephalopathy of mild degree. 
Although our experience is limited, we feel in a position to 
comment about the operation. For some conditions this 
shunt should not be attempted, e.g., an absent left kidney, 
thrombosed renal vein, or thrombosed splenic vein. In the 
past, severe ascites was considered an absolute contrain-
dication to the operation, but Warren now uses a per-
itoneovenous shunt in these patients after constructing a 
distal splenorenal shunt (personal communication, 1979). 
There are other conditions in which the shunt may prove 
difficult or inappropriate; for example, severe chronic pan-
creatitis can make the splenic vein extremely difficult to 
dissect from the pancreas. A splenic vein with a large 
convexity cephalad requires a much longer dissection from 
the pancreas in order to get a section of vein long enough 
to bring it down to the renal vein. Finally, in a small number 
of patients who have an extremely small splenic vein, it 
would seem inappropriate to join such a vein to the left 
renal vein in order to decompress gastro-esophageal 
varices. 
Although it has not yet been shown that patients live longer 
after this operation, we believe that its lower incidence of 
encephalopathy currently makes it the best operation in 
good risk patients. 
Summary 
We believe a selective approach to bleeding esophageal 
varices may produce improved results in the future. In the 
emergency situation and in patients with poor liver func-
tion, shunt operations should be avoided; and injection 
sclerotherapy or transhepatic obliteration of varices should 
be undertaken to stop bleeding. In elective surgery, with 
good risk patients, the Warren shunt currently appears to 
be the best operation to prevent bleeding from varices. 
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